ANVISA – likely no scaling [Regulatives / Guidelines]
❝ Whether for Brazil the BE criterion is similar to Europe approach or USA approach?
AFAIK neither; i.e., no scaling.
❝ What is the BE criterion for Replicate study designs (2 treatments, 4 periods replicate) for Brazil submission.
❝ As per Brazil guideline “Evidence Guide for relative bioavailability/bioequivalence medicines” it is given in statistical analysis section 3.2 (f) that “Other limits of 90% CI for Cmax, previously established in the protocol, may be accepted by scientific justifications”.
❝ The above criterion given is for two-way cross over study.
No, section 3.2 deals with all types of designs.
❝ The same is applicable for replicate studies are not.
See above. Resolution 898 (29 May 2003) suggests replicated designs for CVintra ≥30%. Resolutions 896 (29 May 2003) and 1170 (19 April 2006) you quoted above allow other (=wider) acceptance limits – but already fixed in the protocol. This is not reference-scaling (like for the FDA and EMA), where these limits are based on CVWR estimated in the study. I guess this method is similar to the one mentioned in the obsolte European Q&A-document from 2006 where 75–133% for Cmax were acceptable if CVWR >30% was shown in a replicate design.
But: ANVISA’s website is a black hole (sink of information) and the above may be outdated. If you want to be sure send an e-mail to bioequivalenciaanvisa.gov.br.
Dif-tor heh smusma 🖖🏼 Довге життя Україна!
Helmut Schütz
The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Complete thread:
- Replicate study design for Brazil submission balakotu 2012-11-14 09:49 [Regulatives / Guidelines]
- ANVISA – likely no scalingHelmut 2012-11-14 15:02
- ANVISA – likely no scaling luvblooms 2012-11-16 05:27
- ANVISA: strange Helmut 2012-11-16 14:14
- ANVISA – likely no scaling luvblooms 2012-11-16 05:27
- ANVISA – likely no scalingHelmut 2012-11-14 15:02